Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces First Quarter 2004 Financial Results and Outlook Conference Call and Webcast
What: First Quarter 2004 Financial Results and Outlook Conference
When: Tuesday, May 4, 2004 at 5:00pm ET
Where: Visit the Events page under Investor Information on the
Exelixis website at www.exelixis.com/index.asp?secPage=events
Archived Replay available through May 12, 2004 by visiting
Replay: www.exelixis.com/index.asp?secPage=events or
Contact: Jane M. Green, Ph.D., V.P., Corporate Communications,
Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery
company dedicated to the discovery and development of novel therapeutics. The
company is leveraging its fully integrated gene-to-drug platform to fuel the
growth of its proprietary drug pipeline. Exelixis' development pipeline
includes: XL119, which is anticipated to enter a Phase 3 clinical trial as a
potential treatment for bile duct tumors; XL784, which has completed a Phase 1
clinical trial; XL647, an anticancer compound that is anticipated to enter a
Phase 1 clinical trial; XL999, XL844, XL820 and XL880, anticancer compounds
that are potential IND candidates; and multiple compounds in preclinical
development. Exelixis has established broad corporate alliances with major
pharmaceutical and biotechnology companies, including GlaxoSmithKline and
Bristol-Myers Squibb Company. The company has also established agricultural
research collaborations with Bayer CropScience, Dow AgroSciences and Renessen
LLC. Other partners include Merck & Co., Inc., Schering-Plough Research
Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc.
For more information, please visit the company's web site at www.exelixis.com.
NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.
SOURCE Exelixis, Inc.
/CONTACT: Jane M. Green, Ph.D., V.P., Corporate Communications of
Exelixis, Inc., +1-650-837-7579/
/Web site: http://www.exelixis.com /
/Audio: http://www.firstcallevents.com/service/ajwz404191143gf12.html /
CO: Exelixis, Inc.
IN: HEA MTC BIO
-- SFTU130 --
8163 04/20/2004 13:38 EDT http://www.prnewswire.com